5274-99-7

Basic information

• Product Name: 1-BENZOYLPIPERIDINE-4-CARBOXYLIC ACID
• Synonyms: TIMTEC-BB SBB003259;1-BENZOYLPIPERIDINE-4-CARBOXYLIC ACID;1-BENZOYLPIPERIDINO-4-CARBOXYLIC ACID;Benzoylpiperidinecarboxylicacid;1-Benzoylpiperidine-4-carboxylic acid 98%;1-Benzoylpiperidine-4-carbonsSre;4-piperidinecarboxylic acid, 1-benzoyl-;1-(benzoyl)isonipecotic acid
• CAS NO: 5274-99-7
• Molecular Formula: C₁₃H₁₅NO₃
• Molecular Weight: 233.26
• EINECS: 226-099-2
• Product Categories: pharmacetical;Piperidine
• Mol File: 5274-99-7.mol
• Article Data: 18

Chemical Properties

• Melting Point: 144-146°C
• Boiling Point: 438.8 °C at 760 mmHg
• Flash Point: 219.2 °C
• Appearance: /
• Density: 1.248g/cm³
• Vapor Pressure: 1.78E-08mmHg at 25°C
• Refractive Index: 1.582
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 4.45±0.20(Predicted)
• CAS DataBase Reference: 1-BENZOYLPIPERIDINE-4-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 1-BENZOYLPIPERIDINE-4-CARBOXYLIC ACID(5274-99-7)
• EPA Substance Registry System: 1-BENZOYLPIPERIDINE-4-CARBOXYLIC ACID(5274-99-7)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• HazardClass: IRRITANT
• Hazardous Substances Data: 5274-99-7(Hazardous Substances Data)

Usage

General Description

The chemical 1-benzoylpiperidine-4-carboxylic acid is a heterocyclic compound that contains a piperidine ring and a benzoyl group. It is a derivative of piperidine, which is a six-membered nitrogen-containing ring. 1-BENZOYLPIPERIDINE-4-CARBOXYLIC ACID is used in organic and pharmaceutical chemistry as a building block for the synthesis of various biologically active compounds, including pharmaceutical drugs and agrochemicals. It has demonstrated potential as an intermediate in the synthesis of various pharmaceuticals, including drugs for the treatment of central nervous system disorders and cardiovascular diseases. Additionally, it has also been studied for its potential antitumor and antiviral activities, making it an important compound for drug discovery and development.

InChI:InChI=1/C13H15NO3/c15-12(10-4-2-1-3-5-10)14-8-6-11(7-9-14)13(16)17/h1-5,11H,6-9H2,(H,16,17)

Upstream product

• 136081-74-8 ethyl 1-benzoyl-4-piperidine-carboxylate 
• 98-88-4 benzoyl chloride 
• 498-94-2 isonipecotic acid 
• 1126-09-6 4-carbethoxypiperidine 

Downstream Products

• 228852-07-1 1-(2-aminoethyl-1,1-d2)-4-(4-nitrobenzoyl)piperidine 
• 228852-06-0 ethyl N-(2-(4-(4-nitrobenzoyl)piperidin-1-yl)ethyl-2,2-d2)carbamate 
• 228852-04-8 3-(2-(4-(4-nitrobenzoyl)-piperidin-1-yl)-ethyl-2,2-d2)-1,2-dihydro-2-thioxoquinazoline 
• 145851-04-3 (4-nitrophenyl)(piperidin-4-yl)methanone 
• 116167-40-9 2-bromo-1-(1-benzoyl-4-piperidyl)-1-ethanone 
• 757236-90-1 2-amino-N-(1-benzyl-piperidin-4-ylmethyl)-acetamide 
• 375355-32-1 1-benzoylpiperidine-4-carboxamide 
• 88915-26-8 4-aminomethyl-1-benzylpiperidine 
• 67686-01-5 1-benzyl-4-piperidinemethanol 
• 115755-50-5 1-benzoyl-4-piperidinecarbonyl chloride 
• 107264-22-2 C₂₆H₂₄N₂O₃ 
• 82902-54-3 phenyl(4-phenylpiperidin-1-yl)methanone 
• 119-61-9 benzophenone 

Relevant articles and documents

Design and synthesis of donepezil analogues as dual AChE and BACE-1 inhibitors

Multi-target-directed ligands (MTDLs) centered on β-secretase 1 (BACE-1) inhibition are emerging as innovative therapeutics in addressing the complexity of neurodegenerative diseases. A new series of donepezil analogues was designed, synthesized and evaluated as MTDLs against neurodegenerative diseases. Profiling of donepezil, a potent acetylcholinesterase (hAChE) inhibitor, into BACE-1 inhibition was achieved through introduction of backbone amide linkers to the designed compounds which are capable of hydrogen-bonding with BACE-1 catalytic site. In vitro assays and molecular modeling studies revealed the dual mode of action of compounds 4–6 against hAChE and BACE-1. Notably, compound 4 displayed potent hAChE inhibition (IC50 value of 4.11 nM) and BACE-1 inhibition (IC50 value of 18.3 nM) in comparison to donepezil (IC50 values of 6.21 and 194 nM against hAChE and BACE-1, respectively). Moreover, 4 revealed potential metal chelating property, low toxicity on SH-SY5Y neuroblastoma cells and ability to cross the blood–brain barrier (BBB) in PAMPA-BBB assay which renders 4 a potential lead for further optimization of novel small ligands for the treatment of Alzheimer's disease.

CASPASE INHIBITOR AND PHARMACEUTICAL COMPOSITION, USE AND THERAPEUTIC METHOD THEREOF

Disclosed are a class of compounds as a caspase inhibitor, and in particular the compound as shown in formula (I) or a pharmaceutically acceptable salt thereof, and the use of the compound in treating caspase-related diseases.

The Magic of Crystal Structure-Based Inhibitor Optimization: Development of a Butyrylcholinesterase Inhibitor with Picomolar Affinity and in Vivo Activity

The enzymatic activity of butyrylcholinesterase (BChE) in the brain increases with the progression of Alzheimer's disease, thus classifying BChE as a promising drug target in advanced Alzheimer's disease. We used structure-based drug discovery approaches to develop potent, selective, and reversible human BChE inhibitors. The most potent, compound 3, had a picomolar inhibition constant versus BChE due to strong cation-π interactions, as revealed by the solved crystal structure of its complex with human BChE. Additionally, compound 3 inhibits BChE ex vivo and is noncytotoxic. In vitro pharmacokinetic experiments show that compound 3 is highly protein bound, highly permeable, and metabolically stable. Finally, compound 3 crosses the blood-brain barrier, and it improves memory, cognitive functions, and learning abilities of mice in a scopolamine model of dementia. Compound 3 is thus a promising advanced lead compound for the development of drugs for alleviating symptoms of cholinergic hypofunction in patients with advanced Alzheimer's disease.